Oddo BHF Asset Management Sas Acquires 12,552 Shares of AbbVie Inc. $ABBV

Oddo BHF Asset Management Sas lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 28.2% during the fourth quarter, HoldingsChannel reports. The firm owned 57,067 shares of the company’s stock after purchasing an additional 12,552 shares during the quarter. Oddo BHF Asset Management Sas’ holdings in AbbVie were worth $13,039,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Bank of Jackson Hole Trust increased its holdings in AbbVie by 0.6% in the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after acquiring an additional 44 shares during the last quarter. Eclectic Associates Inc. ADV increased its holdings in AbbVie by 0.8% in the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after acquiring an additional 45 shares during the last quarter. Hardin Capital Partners LLC increased its holdings in AbbVie by 1.4% in the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after acquiring an additional 46 shares during the last quarter. Dogwood Wealth Management LLC boosted its holdings in AbbVie by 10.8% in the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after buying an additional 46 shares during the period. Finally, Quantum Private Wealth LLC grew its stake in AbbVie by 2.0% in the 4th quarter. Quantum Private Wealth LLC now owns 2,376 shares of the company’s stock valued at $543,000 after buying an additional 46 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on ABBV. Canaccord Genuity Group increased their target price on AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Morgan Stanley lifted their target price on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Finally, Barclays assumed coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $253.43.

AbbVie Trading Down 2.8%

Shares of NYSE ABBV opened at $221.42 on Tuesday. AbbVie Inc. has a 12 month low of $181.73 and a 12 month high of $244.81. The firm has a market capitalization of $391.20 billion, a price-to-earnings ratio of 109.07, a PEG ratio of 0.70 and a beta of 0.32. The business has a 50-day moving average of $211.30 and a 200-day moving average of $218.93.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the firm earned $2.46 earnings per share. AbbVie’s revenue was up 12.4% on a year-over-year basis. On average, analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.